Targeted Genetics will have five clinical trial programs following Rgene Therapeutics acquisition.
Executive Summary
TARGETED GENETICS WILL HAVE FIVE CLINICAL PROGRAMS AFTER RGENE ACQUISITION announced April 16. Acquisition of The Woodlands, Tex.-based Rgene Therapeutics gives Targeted Genetics the rights to its proprietary non-viral gene delivery technology and the E1A tumor suppression gene complexed with DC-cholesterol (RGG-0853), which has received orphan drug designation for advanced ovarian cancer and is now in Phase I trials for ovarian and breast cancer treatment.